David Watson compensation by year
Apellis Pharmaceuticals Summary Compensation Table · all 3 fiscal years held| Component | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Salary | $445,827 | $479,193 | $513,078 |
| Bonus | $222,750 | $271,688 | $211,107 |
| Stock awards | $1,274,326 | $2,814,940 | $1,574,492 |
| Option awards | $1,120,098 | $1,306,582 | $1,577,122 |
| Non-equity incentive | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $6,772 | $13,486 | $15,922 |
| Total | $3,069,773 | $4,885,889 | $3,891,721 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Apellis Pharmaceuticals, Inc. DEF 14A filed April 23, 2025, accession 0000950170-25-056966, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 40,092 | $1,279,336 | — |
| RSU | 23,748 | $757,799 | — |
| RSU | 17,969 | $573,391 | — |
| RSU | 1,875 | $59,831 | — |
| Option | 938 | — | $44.90 |
| Option | 13,808 | — | $35.46 |
| Option | 19,640 | — | $52.66 |
| Option | 34,533 | — | $66.30 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Apellis Pharmaceuticals, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
38 Form 4 lines since the FY2024 proxy (filed April 23, 2025)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-05-14 | Disposition to the issuer | — | 55,986 | — | 0 |
| 2026-05-14 | Disposition to the issuer | — | 7,363 | — | 0 |
| 2026-05-14 | Disposition to the issuer | — | 32,072 | — | 0 |
| 2026-05-14 | Disposition to the issuer derivative | — | 82,500 | — | 0 |
| 2026-05-14 | Grant or award | — | 28,508 | — | 28,508 |
| 2026-05-14 | Grant or award | — | 55,986 | — | 55,986 |
| 2026-05-14 | Grant or award | — | 27,993 | — | 27,993 |
| 2026-05-14 | Disposition to the issuer derivative | — | 14,000 | — | 0 |
The 8 most recent of 38 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Apellis Pharmaceuticals’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Cedric Francois | President & Chief Executive Officer | $10,957,451 |
| Caroline Baumal | Chief Medical Officer | $4,407,128 |
| Adam Townsend | Chief Commercial Officer | $3,956,053 |
| Timothy Sullivan | Chief Financial Officer | $3,949,075 |
| David Watson · this page | General Counsel | $3,891,721 |
The full Apellis Pharmaceuticals compensation record
free company briefThis page is one person within Apellis Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Apellis Pharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Apellis Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat